@gileadsciences – John Martin – Flemington, NJ March 24, 2020 – Covid-19 EmphyCorp News: As Reported in The Lancet ?

Robert Millar sent a message to John Martin that said:

Flemington, NJ March 24, 2020 - Covid-19
EmphyCorp News: As Reported in The Lancet – Clinical Features of Patients Infected with the 2019 novel Coronavirus in Wuhan, China -
EmphyCorp Rx N115 Non-Steroidal Nasal Spray could be used as a potential treatment to help alleviate the symptoms associated with the Coronavirus infections: hypoxemia, lung inflammation, inflammatory cytokines, coughing, and to reduce the rate and spread of infection in healthy individuals with no underlying health conditions and no COVID-19 infection.

Hi Daniel,

I thought you might be interested in our PR Newswire Press Release on March 24th.

If you have any questions, please email me.

Best Regards, Robert Millar
President, EmphyCorp Pharmaceutical


Dr. Alain Martin (70+ Global Drug Patents) is the creator of our Worldwide Patented N115 Rx Non-Steroidal Nasal Spray Technology with no known side effects and all Phase III Ready for Pulmonary Fibrosis (Orphan Drug – completed Phase III and FDA submission), Cystic Fibrosis (Orphan Drug), COPD, Unmet Needs (30-60 Million Americans that are Diabetic/Hypertensive/Pregnant/Children with Allergic Rhinitis/ Chronic Rhinosinusitis /COPD/Asthma that should not take Steroid Nasal and Oral Sprays), Alzheimer’s, Concussions, Cancer Pre-Treatment and is also the creator of Advanced Neosporin, Lubriderm, Rx Rezulin (Type II Diabetes), Cool Mint Listerine, Early Pregnancy Test (EPT), and our sister company’s (20) new Patented Drug Free Skincare Products ready to launch, Drug Free Post Laser Aftercare Products for Dermatologists/Plastic Surgeons ready to launch, and Rx Drugs for Topical Melanoma, Eczema (Atopic Dermatitis), Injectable for Inoperable Tumors, and new Patented Pet Product ready to launch.

Comments are closed.